+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The Scandinavian Multi-Infarct Dementia Trial: A double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia



The Scandinavian Multi-Infarct Dementia Trial: A double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia



Journal of the Neurological Sciences 175(2): 116-123



Vascular dementia is a major cause of mental and physical disability in Western countries. Treatment of vascular dementia is currently based on the recognition and control of vascular risk factors, while specific drugs have not been approved yet. The aim of the present multinational, double-blind, placebo-controlled study was to evaluate the safety and efficacy of nimodipine administered for as long as 26 weeks in improving cognition or slowing cognitive deterioration in patients defined as having multi-infarct dementia (DSM-III-R criteria). Two hundred and fifty-nine patients were included (128 nimodipine, 131 placebo), and 251 were available for the intention-to-treat analysis. No significant difference between drug-treated and placebo patients was noted on the Gottfries-Brâne-Steen scale score (primary efficacy criterion), the remaining neuropsychological tests (Zahlen-Verbindungs-Test, Fuld-Object-Memory Evaluation, Word Fluency Test, Digit Span, Mini-Mental State Examination), and the functional scales (index of Activity of Daily Living, Instrumental Activity of Daily Living, Rapid Disability Scale, Clinical Dementia Rating), although the majority of changes were in favor of the active drug group. A lower incidence of cerebrovascular and cardiac events was observed in the nimodipine-treated patients in comparison with the placebo group. This study failed to show a significant effect of nimodipine on cognitive, social or global assessments in patients defined as affected by multi-infarct dementia according to the DSM-III-R criteria. A post-hoc analysis (presented in an accompanying paper) suggests that nimodipine may have a favorable effect in the subgroup of patients defined as affected by subcortical (small vessel) vascular dementia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011472623

Download citation: RISBibTeXText

PMID: 10831772

DOI: 10.1016/s0022-510x(00)00301-4


Related references

Idebenone in the treatment of multi-infarct dementia: A randomised, double-blind, placebo controlled multicentre trial. Archives of Gerontology and Geriatrics 15(3): 271-278, 1992

Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. Journal of the Neurological Sciences 175(2): 124-134, 2000

Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial. Current Medical Research and Opinion 11(8): 491-500, 1989

Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: A double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 117(4): 385-395, 1995

Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. Neuropsychobiology 21(3): 141-145, 1989

Oxiracetam in the Treatment of Primary Degenerative and Multi-Infarct Dementia: A Double-Blind, Placebo-Controlled Study. Neuropsychobiology 21(3): 141-145, 1989

Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia. Archives of Gerontology and Geriatrics 15(3): 239-248, 1992

Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 36(6): 297-303, 2003

Controlled clinical trial of daily aspirin therapy in multi infarct dementia. Stroke 19(1): 148, 1988

Nifedipine in acute myocardial infarction an assessment of left ventricular function infarct size and infarct expansion a double blind randomized placebo controlled trial. British Heart Journal 59(4): 411-418, 1988

A double blind placebo and piracetam controlled multicenter trial of vinpocetine in dementia of alzheimers type and vascular dementia. Neurobiology of Aging 13(Suppl. 1): S127, 1992

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet. Neurology 9(10): 969-977, 2010

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet. Neurology 8(7): 613-618, 2009

Long-term experience of a trial in multi-infarct dementia. Neuroepidemiology 9(4): 228-232, 1990

Long-Term Experience of a Trial in Multi-Infarct Dementia. Neuroepidemiology 9(4): 228-232, 1990